试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-31
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
编号:NCT03619005登记状态:入组前撤回企业 / 申办者:EndoCeutics Inc.
药物 / 成分:Placebo Vaginal Insert、Prasterone 6.5 mg (0.50%) Vaginal Insert
登记的停止原因(原文):Business decision to not continue this study (only few subjects were screened).
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-31
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
编号:NCT03740945登记状态:入组前撤回企业 / 申办者:EndoCeutics Inc.
药物 / 成分:Placebo、Prasterone (DHEA)
登记的停止原因(原文):Business decision to not perform this study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-31
Liposomal Bupivacaine After Cesarean Delivery
编号:NCT03907813登记状态:入组前撤回企业 / 申办者:Wright State University
药物 / 成分:Exparel、Saline infiltration
登记的停止原因(原文):change in design
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-31
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
编号:NCT04220892登记状态:入组前撤回企业 / 申办者:Jose Carrillo
药物 / 成分:Pembrolizumab、Pemetrexed、Abemaciclib
登记的停止原因(原文):One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab + abemaciclib study arm is removed due to toxicity seen in other trials.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-31
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
编号:NCT04412252登记状态:入组前撤回企业 / 申办者:Pfizer
药物 / 成分:Tofacitinib、Placebo
登记的停止原因(原文):Due to the pursuit of other SARS-CoV-2-related research including alternative trials with tofacitinib, this trial was canceled prior to subject enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-29
Gabapentin for Relief of Immediate Postoperative Pain
编号:NCT03750773登记状态:入组前撤回企业 / 申办者:Indiana University
药物 / 成分:Gabapentin 600mg、Placebo oral capsule
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-28
Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
编号:NCT03430687登记状态:入组前撤回企业 / 申办者:University of California, San Francisco
药物 / 成分:Laboratory Biomarker Analysis、Talimogene Laherparepvec
登记的停止原因(原文):Investigators prefer to pursue other studies
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-27
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
编号:NCT01826864登记状态:入组前撤回企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:sargramostim、sentinel lymph node biopsy、laboratory biomarker analysis、hypertonic saline
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-27
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
编号:NCT02263898登记状态:入组前撤回企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:Raf kinase inhibitor LGX818、binimetinib、laboratory biomarker analysis
登记的停止原因(原文):closed without enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-27
Residual Dental Pulp Tissue and Cord Blood Stem Cells
编号:NCT04040127登记状态:入组前撤回企业 / 申办者:University of California, San Francisco
药物 / 成分:Cord blood stem cells、Saline solution
登记的停止原因(原文):Did not obtain IRB approval
查看官方原始记录 ↗